secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001171843-25-007075
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q3 net loss $31.5M; Phase 2 HBV study enrolling; cash $99.1M
-------------------------------------------------------------------

- Net loss of $31.5M in Q3 2025 vs $19.3M in Q3 2024; diluted EPS loss of $3.04.
- Cash, cash equivalents and investments $99.1M as of Sep 30, 2025; runway into Q3 2026.
- Phase 2 B-SUPREME trial of pevifoscorvir sodium (CAM-E) for chronic HBV enrolled first patient Aug 2025; interim data 2026.
- Preclinical combo data with ALG-055009 (THR-β) and incretin RAs showed synergistic weight loss; out-licensing discussions ongoing.
- R&D expenses rose to $23.9M (from $16.8M) driven by Phase 2 costs; G&A $5.2M (from $4.6M) due to legal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184325007075/0001171843-25-007075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184325007075/f8k_110525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-007075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer